---
schema_version: "secwatch.filing_event.v1"
accession: "0001411685-25-000046"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2025-06-17T23:59:59+00:00"
generated_at: "2026-05-19T04:29:17.485589+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vistagen reports FY2025 net loss $51.4M; cash $80.5M; advances PALISADE fasedienol trials

## Summary
- FY2025 net loss $51.4M (vs $29.4M prior year); R&D expenses doubled to $39.4M on fasedienol and PH80 programs.
- Cash, cash equivalents and marketable securities $80.5M as of March 31, 2025.
- PALISADE-3 fasedienol topline results expected Q4 2025; PALISADE-4 results expected H1 2026.
- Filed prospectus supplement to sell up to $175M common stock via ATM (replacing $100M prior); ~$3.4M already sold.
- Itruvone for MDD planning further Phase 2; PH80 for menopausal hot flashes preparing U.S. IND.

## SEC filing metadata
- accession: 0001411685-25-000046
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2025-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000141168525000046/0001411685-25-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000141168525000046/vtgn-20250617.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001411685-25-000046
- JSON: https://secwatch.observer/filing/0001411685-25-000046.json
- Plain text: https://secwatch.observer/filing/0001411685-25-000046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.